SACUBITRIL; VALSARTAN | A213680 | BIOCON PHARMA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc., et al. 4 patentsANDA 213764, 213631, 213680, 213605, 213676, 213808, 213809, 213671, 213577, 213604sacubitril/valsartan | D. Del. | 2019-10-17 | Terminated 2024-09-06 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.5859
per ea
Lowest NADAC/Unit
$0.5306
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70377003312SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 70377003313SACUBITRIL-VALSARTAN 97-103 MG | $0.5859 | EA | Generic | — | 2026-06-17 |
| 70377003212SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 70377003213SACUBITRIL-VALSARTAN 49-51 MG | $0.5485 | EA | Generic | — | 2026-06-17 |
| 70377003112SACUBITRIL-VALSARTAN 24-26 MG | $0.5306 | EA | Generic | — | 2026-06-17 |
| 70377003113SACUBITRIL-VALSARTAN 24-26 MG | $0.5306 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.